COMPOSITION
Cinaron® tablet : Each tablet contains Cinnarizine BP 15 mg.

PHARMACOLOGY
Cinnarizine’s actions in the treatment of peripheral vascular disease are due to its anti-vasoconstictor properties, its action on blood hyperviscosity and its anti-ischaemic effect. Anti-vasoconstriction is thought to be through a calcium blocker mechanism and is evident selectively in vascular smooth muscle. Increased peripheral muscle blood flow may be mediated by prevention of calcium entry into ischaemic erythrocytes, thereby prescribing flexibility.

INDICATION
1. Cerebral circulatory disorders
   a. Prophylaxis and maintenance therapy for symptoms of cerebral vascular spasms and arteriosclerosis such as: dizziness, ear buzzing (tinnitus), vascular headache, unsociability, irritability, fatigue, sleep rhythm disorders such as premature awakening, involutional depressions, loss of memory, lack of concentration, incontinence and other disorders due to aging.
   b. Sequelae of cerebral and cranial trauma.
   c. Postapoplectic disorders
   d. Migraine
2. Peripheral circulatory disorders
   Prophylaxis and maintenance therapy for symptoms of vascular spasms and arteriosclerosis (obliterating arteritis, thromboangiitis, Raynaud’s disease, diabetes, acrocyanosis pernio, etc.) such as intermittent claudication, trophic disturbances, pregangrene, trophic and varicose ulcers, paresthesia, nocturnal cramps, cold extremities.
3. Disorders of balance
   a. Prophylaxis and maintenance therapy for symptoms of labyrinthine arteriosclerosis, vestibular irritability, Meniere’s syndrome, such as vertigo, dizziness, giddiness, syncopal attacks, tinnitus, nystagmus, nausea and vomiting.
   b. Prophylaxis of motion sickness.
DOSAGE AND ADMINISTRATION

Usual adult dose: 15 to 30 mg three times daily.

Children (5 to 12 years): Half of the adult dose.

Motion sickness: A dose of 30 mg two hours before the start of the journey and 15 mg every 8 hours during the journey.

Peripheral arterial diseases: 75 mg two or three times daily.

CONTRAINDICATION AND PRECAUTION

There are no specific contraindications. It has been found to decrease blood pressure significantly. However, the drug should be used with reasonable caution in hypotensive patients.

Cinnarizine may cause drowsiness; patients affected in this way should not drive or operate machinery. Avoid alcoholic drink.

SIDE EFFECT

Side effects such as somnolence and gastrointestinal disturbances are extremely rare. They are transient and may be readily prevented by achieving the optimal dosage gradually.

Allergic skin reactions and fatigue have been reported on rare occasions. An aggravation or appearance of extrapyramidal symptoms has been reported extremely rarely in elderly people during prolonged therapy. The treatment should be reduced or stopped in such cases.

DRUG INTERACTION

No drug interactions have been seen with Cinnarizine when administered concomitantly with antihypertensives, diuretics, anticoagulants or hypoglycaemics.

USE IN PREGNANCY AND LACTATION

The safety of Cinnarizine in human pregnancy has not been established although studies in animals have not demonstrated teratogenic effects. Therefore, it is not advisable to administer Cinnarizine in pregnancy.

HOW SUPPLIED

Cinaron® tablet : Box containing 20 x 10 tablets in blister pack.